ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
其他

Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST)

Stefanie Jilg; Michael Rassner; Jacqueline Maier; Silvia Waldeck; Victoria Kehl; Marie Follo; Ulrike Philipp; Andreas Sauter; Katja Specht; Jan Mitschke; Thoralf Lange; Sebastian Bauer; Philipp J Jost; Christian Peschel; Justus Duyster; Timo Gaiser; Peter Hohenberger; Nikolas Bubnoff
2019DOI: 10.1002/ijc.32282
12被引12阅读
引用收藏
分享

摘要

This prospective trial aimed to investigate whether tumor‐specific cKIT and PDGFRA mutations can be detected and quantified in circulating tumor (ct)DNA in patients with active GIST, and whether detection indicates disease activity. We included 25 patients with active disease and cKIT or PDGFRA mutations detected in tissue. Mutant ctDNA was detected in the peripheral blood plasma using allele‐specific ligation (L‐)PCR and droplet digital (d)PCR. CtDNA harboring tumor‐specific cKIT or PDGFRA mutations was detected at least once in 16 out of 25 patients using L‐PCR (64%) and in 20 out of 25 patients with dPCR (80%). Using dPCR, the absolute numbers of ctDNA fragments (DNA copies/ml) and the mutant allele frequency (MAF; in percent of wild‐type control) strongly correlated with tumor size expressed as RECIST1.1 sum of diameter (SOD) in mm (ρ = 0.3719 and 0.408, respectively, p < 0.0001) and response status (ρ = 0.3939 and 0.392, respectively, p < 0.0001 and p < 0.001). Specificity of dPCR for detection of progression was 79.2% with a sensitivity of 55.2% and dPCR discriminated CR from active disease with a specificity of 96% and s sensitivity of 44.7%. With L‐PCR, correlations of MAF with tumor size and response status were less prominent. Serial ctDNA measurement reflected individual disease courses over time. Targeted panel sequencing of four patients detected additional driver mutations in all cases and secondary resistance mutations in two cases. Thus, ctDNA indicates disease activity in patients with GIST and should be incorporated as companion biomarker in future prospective trials.

学科与关键词

关键词
Liquid biopsyCirculating tumor DNAGISTCancer biomarker

基本信息

发表日期
2019
DOI
10.1002/ijc.32282

作者

  • S

    Stefanie Jilg (第一作者)

  • M

    Michael Rassner

查看全部 18 位作者收起作者
  • J

    Jacqueline Maier

  • S

    Silvia Waldeck

  • V

    Victoria Kehl

  • M

    Marie Follo

  • U

    Ulrike Philipp

  • A

    Andreas Sauter

  • K

    Katja Specht

  • J

    Jan Mitschke

  • T

    Thoralf Lange

  • S

    Sebastian Bauer

  • P

    Philipp J Jost

  • C

    Christian Peschel

  • J

    Justus Duyster

  • T

    Timo Gaiser

  • P

    Peter Hohenberger

  • N

    Nikolas Bubnoff

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417